Sanofi is doubling down on early-stage biotech funding by adding $625 million to its corporate venture fund, Sanofi Ventures. This brings the total capital to $1.4 billion, enabling increased support for young biotech and digital health startups. Amid constrained funding environments, Sanofi seeks to lead or co-lead investment rounds, bridging gaps where traditional venture capital is cautious. The fund’s aim is to foster innovation and bolster biopharma partnerships and acquisitions.